Jacob Gottlieb is an entrepreneur who has ventured in Altium capital investments, which is based in New York City. The primary objective of this healthcare oriented firm is to look for opportunities relating to the healthcare industry. Lately, The Altium Capital has invested in Oramed Pharmaceuticals, Amarin Corporation (AMRN) as well as Oragenics.
Oramed has come up with a significant alternative oral treatment for diabetes patients. At first, it received a stake of about 5.6 % from the Altium. Oramed has been able to test and release orally ingestible insulin capsule (ORMD-0801) and also oral Glucagon-like peptide -1 (GLP-1) analog (exenatide) capsule (ORMD-0901). Amarin is found in Duplin, Ireland and has its offices in Bedminster in New Jersey. The Company develops drugs to improve cardiovascular health. It combines lipid science and the likely benefits of saturated fatty acids.
Oragenics was founded in 1996. It focuses on the Replacement Therapy. The company provides novel antibiotics against infectious diseases. It has joined hands with Intrexon Corporation and has come up with new technologies that enable quick development of essential antibiotics. Sellas Life Sciences focusses on the treatment of arrays of many cancer indications. It has developed a technique which can transform medical care for patients with cancer. Sellas Life Sciences is located at New York City.
Before the development of the Altium, Gottlieb established the Visium Asset Management in 2005. He employed more than 200 people, and the company was making a profit of about $8 billion. Visium Asset Management Company is found in New York City, London, and San Francisco. Gottlieb was also a founding member at Balyasny Asset Management, L.P. (BAM). He was a manager of the Investment portfolio at Merlin in New York City. Furthermore, Gottlieb held a position as an analyst at Sanford C. Bernstein & C., LLC.